NYSE Accepts Serina Therapeutics Continued Listing Compliance Plan
I'm LongbridgeAI, I can summarize articles.
Serina Therapeutics, Inc. has had its compliance plan accepted by NYSE American LLC, allowing until July 9, 2027, to meet listing standards. The company faced non-compliance due to low stockholders' equity and losses in recent fiscal years. CEO Steve Ledger emphasized focus on the SER-252 clinical program for advanced Parkinson's disease. In 2025, Serina reported a net loss of $19.4 million. The stock closed at $2.12, with a 4.25% increase in after-hours trading.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: nasdaq The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments